Reintroduction Of Treatment Target For ESAs For Kidney Failure?
Executive Summary
FDA is considering the reintroduction of a hemoglobin target for erythropoiesis-stimulating agents in the treatment of kidney disease, even though it removed similar language earlier this year from product labeling of the anemia therapies